Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing

Dragon Images/Shutterstock.com

The program was to usage the proceeds to money ongoing probe and improvement of ivonescimab, the company's pb drug. Ivonescimab is simply a bispecific antibody that simultaneously targets the 2 proteins connected which crab cells trust to turn and fell from the immune system. The cause is presently the astir intimately watched plus successful Summit's pipeline and is already approved successful China.

Summit had projected the offering conscionable 9 days aft its Chinese spouse Akeso presented Phase 3 information from a China-based lung crab proceedings of ivonescimab. The results showed a 34% simplification successful the hazard of decease compared to a competing therapy. However, a CNBC study raised the interest that the information whitethorn not beryllium arsenic utile to Summit due to the fact that the proceedings was conducted successful China.

CNBC quoted Dr. Suresh Ramalingam, enforcement manager of the Winship Cancer Institute of Emory University, who said: "I'm mindful of the information that this proceedings was done exclusively successful China, and that brings up the question of however bash these information use to diligent populations extracurricular of China, and that volition necessitate aboriginal investigations."

Dr. Ramalingam explained that their concerns are not that the cause doesn't work. In fact, helium called the results bully quality for Chinese patients. Instead, their interest is that 1 can't presume results from a China-only proceedings volition construe to US oregon planetary patients, particularly erstwhile determination are biologic reasons to expect the effect to beryllium different.

Summit Therapeutics Inc. (NASDAQ:SMMT) is simply a clinical-stage biopharmaceutical company. Its pb candidate, ivonescimab, is simply a caller bispecific antibody targeting some PD-1 and VEGF pathways, and is presently being evaluated successful aggregate Phase 3 trials for non-small compartment lung crab and different coagulated tumors.

While we admit the imaginable of SMMT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 High-Growth Micro-Cap Stocks to Buy Now and 10 Best Long-Term Stocks to Invest In According to Bill & Melinda Gates Foundation Trust.

Disclosure: None. Follow Insider Monkey connected Google News.